Theravance Biopharma Inc (TBPH) has a current Price-to-Book (P/B) ratio of 3.95. Compared to its 3-year average P/B ratio of 2.38, the current P/B ratio is approximately 66.16% higher. Relative to its 5-year average P/B ratio of 0.70, the current P/B ratio is about 464.57% higher. Theravance Biopharma Inc (TBPH) has a Forward Free Cash Flow (FCF) yield of approximately 26.47%. Compared to its 3-year average FCF yield of -4.13%, the current FCF yield is approximately -741.33% lower. Relative to its 5-year average FCF yield of -13.11%, the current FCF yield is about -301.94% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TBPH competitors is 18.86, providing a benchmark for relative valuation. Theravance Biopharma Inc Corp (TBPH.O) exhibits a P/S ratio of 8.89, which is -52.87% above the industry average. Given its robust revenue growth of 18.51%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TBPH increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TBPH in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TBPH currently overvalued or undervalued?

What is Theravance Biopharma Inc (TBPH) fair value?

TBPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Theravance Biopharma Inc (TBPH) is between 18.20 to 31.67 according to relative valuation method.

How does TBPH's valuation metrics compare to the industry average?

The average P/S ratio for TBPH's competitors is 18.86, providing a benchmark for relative valuation. Theravance Biopharma Inc Corp (TBPH) exhibits a P/S ratio of 8.89, which is -52.87% above the industry average. Given its robust revenue growth of 18.51%, this premium appears unsustainable.

What is the current P/B ratio for Theravance Biopharma Inc (TBPH) as of Mar 02 2026?

As of Mar 02 2026, Theravance Biopharma Inc (TBPH) has a P/B ratio of 3.95. This indicates that the market values TBPH at 3.95 times its book value.

What is the current FCF Yield for Theravance Biopharma Inc (TBPH) as of Mar 02 2026?

As of Mar 02 2026, Theravance Biopharma Inc (TBPH) has a FCF Yield of 26.47%. This means that for every dollar of Theravance Biopharma Inc's market capitalization, the company generates 26.47 cents in free cash flow.

What is the current Forward P/E ratio for Theravance Biopharma Inc (TBPH) as of Mar 02 2026?

As of Mar 02 2026, Theravance Biopharma Inc (TBPH) has a Forward P/E ratio of 25.06. This means the market is willing to pay $25.06 for every dollar of Theravance Biopharma Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Theravance Biopharma Inc (TBPH) as of Mar 02 2026?

As of Mar 02 2026, Theravance Biopharma Inc (TBPH) has a Forward P/S ratio of 8.89. This means the market is valuing TBPH at $8.89 for every dollar of expected revenue over the next 12 months.

TBPH Valuation